Rafferty Asset Management
SMMT icon

Rafferty Asset Management’s Summit Therapeutics SMMT Stock Holding History

Rafferty Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Sell
206,625
-52,449
-20% -$930K 0.01% 545
2026
Q1 		$4.91M Sell
259,074
-28,736
-10% -$465K 0.02% 363
2025
Q4 		$5.03M Sell
287,810
-51,366
-15% -$966K 0.02% 432
2025
Q3 		$7.01M Buy
339,176
+140,323
+71% +$3.4M 0.02% 357
2025
Q2 		$4.23M Sell
198,853
-30,889
-13% -$704K 0.01% 429
2025
Q1 		$4.43M Sell
229,742
-81,950
-26% -$1.64M 0.02% 395
2024
Q4 		$5.56M Buy
311,692
+203,377
+188% +$3.94M 0.02% 398
2024
Q3 		$2.37M Sell
108,315
-57,583
-35% -$805K 0.01% 589
2024
Q2 		$1.29M Sell
165,898
-484,388
-74% -$2.62M ﹤0.01% 758
2024
Q1 		$2.69M Buy
+650,286
New +$2.58M 0.01% 612

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rafferty Asset Management's SMMT Position: Q2 2026 in Review

Rafferty Asset Management reduced its Summit Therapeutics (SMMT) stake by 20% in Q2 2026, selling an estimated $930K and leaving 206,625 shares worth $3.01M. The position accounts for 0.01% of the portfolio, ranked #545.

Rafferty Asset Management first reported a position in SMMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.01M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Rafferty Asset Management held 206,625 shares of Summit Therapeutics worth $3.01M as of Q2 2026.
  • Rafferty Asset Management sold 52,449 Summit Therapeutics shares in Q2 2026, an estimated $930K.
  • Summit Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #545 holding.
  • Rafferty Asset Management first reported a position in Summit Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Rafferty Asset Management's Summit Therapeutics position peaked at $7.01M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.